QUICK REFERENCE GUIDE

ADMINISTRATOR




NAVICA[™] ADMINISTRATOR

Perform the BinaxNOW™ COVID-19 Ag Card test and communicate encrypted test results using the NAVICA™ Administrator App.



Log in to the NAVICA[™] Administrator App, and select Begin New Test.



Scan the participant's unique NAVICA ID QR code using the camera on your tablet.

a Abbott



Verify the participant's identity with a photo ID.







Collect the nasal swaband perform the test.

(See the BinaxNOW[™] COVID-19 Ag Card Product Insert, including the quality control section, for complete use instructions, warnings, precautions and limitations.)



To enter the result into the NAVICA[™] Administrator App, **rescan the QR** code on the test card to confirm the link between the test and the participant.



Visually interpret the results on the test card and enter the results in the NAVICA Administrator App with a single tap.

NAVICA
NAVICA
in a final field and a field a
Jane Doe (01/30/99)
0081138019511
nd Irons. This means this low levels of indujuryth colored line
colored Control Line in whit. This Control Line connectly, but no
or the Blue Control Line up be repeated.

PINK/PURPLE CONTROL LINE PINK/PURPLE SAMPLE LINE			
	POSITIVE	NEGATIVE	INVALID
	RESULT	RESULT	RESULT

See the Product Insert for full result interpretation instructions.

THE PARTICIPANT WILL RECEIVE A PUSH NOTIFICATION AND BE NOTIFIED VIA EMAIL TO REVIEW THEIR ENCRYPTED RESULT IN THE NAVICA APP.

YOUR FACILITY WILL SEPARATELY NOTIFY THE PARTICIPANT VIA YOUR REGULAR PROCESS FOR LAB TEST REPORTING.

The BinaxNOW™ COVID-19 Ag Card EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

 \odot 2020 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. 120007266-01 09/20

